Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial

Publikation

Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial

Wissenschaftlicher Artikel/Review - 24.02.2017

Huttner Angela, Bernasconi Enos, Viereck Volker, Kavvadias Tilemachos, Kling Kerstin, Ryu Gloria, Hülder Tanja, Gröger Sabine, Scheiner David, Alaimo Cristina, Harbarth Stephan, Poolman Jan, Kuhn Anette, de Vallière Serge, Hatz Christoph, van den Dobbelsteen Germie, Abbanat Darren, Hornacek Alena, Frölich Rahel, Dreyer Anita M, Martin Patricia, Davies Todd, Fae Kellen, van den Nieuwenhof Ingrid, Thoelen Stefan, Fonck Veronica Gambillara

Zitation

Huttner A, Bernasconi E, Viereck V, Kavvadias T, Kling K, Ryu G, Hülder T, Gröger S, Scheiner D, Alaimo C, Harbarth S, Poolman J, Kuhn A, de Vallière S, Hatz C, van den Dobbelsteen G, Abbanat D, Hornacek A, Frölich R, Dreyer A, Martin P, Davies T, Fae K, van den Nieuwenhof I, Thoelen S, Fonck V. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis 2017; 17:528-537.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Lancet Infect Dis 2017; 17

Veröffentlichungsdatum

24.02.2017

eISSN (Online)

1474-4457

Seiten

528-537